BioCentury
ARTICLE | Company News

BMS beats Street, posts ex-U.S. HCV sales

July 24, 2015 1:13 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) reported total revenues of $4.2 billion in 2Q15, including $479 million from ex-U.S. sales of HCV drugs Daklinza daclatasvir and Sunvepra asunaprevir. The overall sales beat the Street's estimate of $3.7 billion, and were up 7% compared to $3.9 billion in 2Q14. The company reported non-GAAP EPS of $0.53, up 10% from $0.48 in the prior year's quarter and beating the consensus estimate of $0.36.

The HCV sales figure included $170 million in deferred revenues from France related to an early access program. BMS markets Daklinza, an HCV NS5A protein inhibitor, and Sunvepra, an HCV NS3 protease inhibitor, in the EU and Japan. ...